

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS



PHM119B
September 2016

Anuj Pathak
Project Analyst

ISBN: 1-62296-345-8



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
SCOPE OF THE STUDY	2
METHODOLOGY AND INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 EXECUTIVE SUMMARY	6
EXECUTIVE SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015-2021 (\$ MILLIONS)</i>	7
CHAPTER 3 INDUSTRY OVERVIEW	10
MAJOR DEVELOPMENTS	10
COAGULATION FACTORS TARGETED TO REDUCE CVD	10
DEVELOPMENT OF ANTIDOTES FOR THROMBIN INHIBITORS	10
Andexanet Alfa	10
Praxbind (Idarucizumab)	11
<i>TABLE 1 PRAXBIND (IDARUCIZUMAB) DRUG LABEL</i>	12
SALES PERFORMANCE OF MAJOR DRUGS PROJECTED THROUGH 2020	12
XARELTO (RIVAROXABAN)	12
ELIQUIS (APIXABAN)	12
PRADAXA (DABIGATRAN ETEXILATE MESYLATE)	13
LOVENOX (ENOXAPARIN)	13
PLAVIX (CLOPIDOGREL)	13
<i>TABLE 2 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	13
PATENT ANALYSIS	14
PATENT BY ASSIGNEE	14
<i>FIGURE 1 COMPANY SHARES OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, JAN. 2011 TO APRIL 2016 (%)</i>	14
<i>FIGURE 2 COMPANY SHARES OF PATENTS ON ANTICOAGULANTS, JAN. 2011 TO APRIL 2016 (%)</i>	15
EPIDEMIC OF CARDIOVASCULAR DISEASE	17
<i>TABLE 3 EPIDEMIC OF CARDIOVASCULAR DISEASES</i>	18
RISK FACTORS AND PREVENTION OF CVD	20
CLASSIFICATION OF CARDIOVASCULAR DISEASES	20
CORONARY HEART DISEASE	20
Prevalence of CHD in the U.S.	21
<i>TABLE 4 CORONARY HEART DISEASE PROFILE</i>	21
<i>TABLE 5 DISTRIBUTION OF HEART DISEASE BY RACE/ETHNICITY, 2013 (%)</i>	22

TOPIC	PAGE NO.
ACUTE MYOCARDIAL INFARCTION	23
<i>TABLE 6 ACUTE MYOCARDIAL INFARCTION DISEASE PROFILE</i>	24
THE CIRCULATORY SYSTEM	25
BLOOD VESSEL STRUCTURE	25
BLOOD FLOW	26
CONDITIONS	27
THROMBUS	27
EMBOLUS	28
ALTERATIONS IN VENOUS FLOW	29
DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM	29
<i>TABLE 7 VIRCHOW'S TRIAD: THREE MAIN FACTORS IN PREDISPOSITION TO PULMONARY EMBOLISM</i>	30
HEMOSTASIS (THE CLOTTING PROCESS)	31
DISEASES ASSOCIATED WITH THROMBOEMBOLISM	32
ACUTE CORONARY SYNDROME	32
ISCHEMIC HEART DISEASE	32
Etiology	33
Mechanisms of Coronary Atherosclerosis	33
Pathophysiology of Ischemia	34
ANGINA PECTORIS	35
CHRONIC ISCHEMIC CARDIOMYOPATHY	35
SUDDEN CARDIAC DEATH	35
ATRIAL FIBRILLATION	36
Causes	36
CEREBROVASCULAR DISEASE	37
STENT THROMBOSIS	38
DEMOGRAPHICS	39
<i>TABLE 8 GLOBAL POPULATION BY SELECTED REGION, 2000-2050 (MILLIONS)</i>	39
<i>TABLE 9 GLOBAL POPULATION GROWTH BY SELECTED REGION, 2000-2050 (AVERAGE PERCENTAGE GROWTH PER YEAR)</i>	40
<i>FIGURE 3 GLOBAL POPULATION GROWTH BY SELECTED REGION, 2000-2050 (AVERAGE PERCENTAGE GROWTH)</i>	40
CV, VTE, AF AND STROKE DEMOGRAPHICS	42
Venous Thromboembolism	42
Venous Thromboembolism and Lifestyle	43
Venous Thromboembolism and Air Travel	43
CHAPTER 4 ANTICOAGULANTS	47
OVERVIEW	47
PRODUCTS	48
LOW MOLECULAR WEIGHT HEPARIN	48
Lovenox	48
<i>TABLE 10 LOVENOX DRUG LABEL</i>	49
Fragmin	50
<i>TABLE 11 FRAGMIN DRUG LABEL</i>	50
Innohep	52
<i>TABLE 12 INNOHEP DRUG LABEL</i>	52
Orgaran	53

TOPIC	PAGE NO.
<i>TABLE 13 ORGARAN DRUG LABEL</i>	54
Normiflo	55
<i>TABLE 14 NORMIFLO DRUG LABEL</i>	56
Embolex	56
<i>TABLE 15 EMBOLEX DRUG LABEL</i>	57
Fraxiparine	57
<i>TABLE 16 FRAXIPARINE DRUG LABEL</i>	58
Ariven/Arteven	58
<i>TABLE 17 ARIVEN/ARTEVEN DRUG LABEL</i>	59
ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS)	59
GLOBAL MARKET FORECAST	60
<i>TABLE 18 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	61
<i>FIGURE 4 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, 2015-2021 (\$ MILLIONS)</i>	61
MARKET BY GEOGRAPHIC REGION	62
<i>TABLE 19 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 (%)</i>	63
<i>FIGURE 5 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 (%)</i>	63
<i>TABLE 20 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 (%)</i>	63
<i>FIGURE 6 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 (%)</i>	64
MARKET BY DRUG TYPE	64
<i>TABLE 21 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	65
<i>TABLE 22 GLOBAL MARKET FOR LOW MOLECULAR WEIGHT HEPARIN BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	65
<i>TABLE 23 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	65
<i>FIGURE 7 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, 2015-2021 (\$ MILLIONS)</i>	65
<i>TABLE 24 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2015 (%)</i>	66
<i>FIGURE 8 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2015 (%)</i>	66
<i>TABLE 25 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2021 (%)</i>	67
<i>FIGURE 9 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2021 (%)</i>	67
COMPETITIVE ANALYSIS	68
<i>TABLE 26 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (\$ MILLIONS/%)</i>	68
<i>FIGURE 10 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)</i>	68
CHAPTER 5 ANTIPLATELETS	71
OVERVIEW	71
PRODUCTS	71
ORAL ANTIPLATELETS	71
Plavix	71
<i>TABLE 27 PLAVIX DRUG LABEL</i>	71
Pletal	72

TOPIC	PAGE NO.
<i>TABLE 28 PLETAL DRUG LABEL</i>	73
Effient	74
<i>TABLE 29 EFFIENT DRUG LABEL</i>	74
Ticlid	75
Brilinta	75
<i>TABLE 30 BRILINTA DRUG LABEL</i>	75
IV ANTIPLATELETS	76
Integrilin	76
<i>TABLE 31 INTEGRILIN DRUG LABEL</i>	77
Aggrastat	78
<i>TABLE 32 AGGRASTAT DRUG LABEL</i>	78
ReoPro	79
<i>TABLE 33 REOPRO DRUG LABEL</i>	80
GLOBAL MARKET FORECAST	80
<i>TABLE 34 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	81
<i>FIGURE 11 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, 2015-2021 (\$ MILLIONS)</i>	81
MARKET BY GEOGRAPHIC REGION	82
<i>TABLE 35 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2015 (%)</i>	82
<i>FIGURE 12 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2015 (%)</i>	83
<i>TABLE 36 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2021 (%)</i>	83
<i>FIGURE 13 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2021 (%)</i>	84
MARKET BY DRUG TYPE	84
<i>TABLE 37 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	85
<i>FIGURE 14 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, 2015-2021 (\$ MILLIONS)</i>	85
<i>TABLE 38 GLOBAL MARKET FOR ORAL ANTIPLATELET DRUGS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	86
<i>TABLE 39 GLOBAL MARKET FOR IV ANTIPLATELET DRUGS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	86
<i>TABLE 40 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2015 (%)</i>	86
<i>FIGURE 15 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2015 (%)</i>	86
<i>TABLE 41 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2021 (%)</i>	87
<i>FIGURE 16 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2021 (%)</i>	88
COMPETITIVE ANALYSIS	88
<i>TABLE 42 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (\$ MILLIONS/%)</i>	88
<i>FIGURE 17 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)</i>	88
CHAPTER 6 THROMBIN INHIBITORS	91
OVERVIEW	91
PRODUCTS	91
DIRECT THROMBIN INHIBITORS	91

TOPIC	PAGE NO.
Argatroban	91
Angiomax	91
Iprivask	91
Pradaxa	92
THROMBOLYTIC AGENTS	92
Thrombolytic Enzymes	92
Tissue Plasminogen Activators	93
Activase	93
Retavase	93
TNKase	93
ATryn	93
DIRECT FACTOR XA INHIBITORS	93
Xarelto	93
Betrixaban	94
Savaysa (Edoxaban)	94
Eliquis	94
GLOBAL THROMBIN INHIBITOR MARKET FORECAST	95
<i>TABLE 43 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	96
<i>FIGURE 18 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, 2015-2021 (\$ MILLIONS)</i>	96
REGIONAL MARKET SHARES OF THROMBIN INHIBITORS	96
<i>TABLE 44 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 (%)</i>	97
<i>FIGURE 19 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 (%)</i>	97
<i>TABLE 45 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 (%)</i>	98
<i>FIGURE 20 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 (%)</i>	98
MARKET BY DRUG TYPE	98
<i>TABLE 46 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	99
<i>FIGURE 21 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, 2015-2021 (\$ MILLIONS)</i>	99
<i>TABLE 47 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, 2015 (%)</i>	100
<i>FIGURE 22 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, 2015 (%)</i>	100
<i>TABLE 48 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 (%)</i>	100
<i>FIGURE 23 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 (%)</i>	101
<i>TABLE 49 GLOBAL MARKET FOR THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 (\$ MILLIONS/%)</i>	101
<i>FIGURE 24 GLOBAL MARKET SHARES OF THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 (%)</i>	101
RESEARCH AND DEVELOPMENT	102
GLOBAL ANTICOAGULANT/ANTITHROMBOTIC MARKET FORECAST	104
<i>TABLE 50 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	105

TOPIC	PAGE NO.
<i>FIGURE 25 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2015-2021 (\$ MILLIONS)</i>	105
<i>TABLE 51 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2015 (%)</i>	106
<i>FIGURE 26 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2015 (%)</i>	106
<i>TABLE 52 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2021 (%)</i>	107
<i>FIGURE 27 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2021 (%)</i>	107
MARKET BY GEOGRAPHIC REGION	107
<i>TABLE 53 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	108
<i>FIGURE 28 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015-2021 (\$ MILLIONS)</i>	108
<i>TABLE 54 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 (%)</i>	109
<i>FIGURE 29 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 (%)</i>	109
<i>TABLE 55 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 (%)</i>	110
<i>FIGURE 30 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 (%)</i>	110
COMPETITIVE ANALYSIS	110
<i>TABLE 56 GLOBAL MARKET FOR ANTITHROMBIN/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (\$ MILLIONS/%)</i>	111
<i>FIGURE 31 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)</i>	111
CHAPTER 7 COMPANY PROFILES	113
ABBOTT LABORATORIES	113
HISTORY	113
RECENT DEVELOPMENTS	114
PRODUCTS	114
LOCATIONS	114
CORPORATE MANAGEMENT	114
ARMETHEON INC.	114
HISTORY	114
PRODUCTS	115
RECENT DEVELOPMENTS	115
CORPORATE MANAGEMENT	115
ASTRAZENECA	115
HISTORY	115
PRODUCTS	115
RECENT DEVELOPMENTS	116
LOCATIONS	116
CORPORATE MANAGEMENT	116
BAXTER INTERNATIONAL	116
HISTORY	116
PRODUCTS	117

TOPIC	PAGE NO.
RECENT DEVELOPMENTS	117
LOCATIONS	117
CORPORATE MANAGEMENT	117
BAYER AG	117
HISTORY	117
PRODUCTS	118
RECENT DEVELOPMENTS	118
LOCATIONS	118
CORPORATE MANAGEMENT	118
BIOVASCULAR INC.	119
HISTORY	119
PRODUCTS	119
LOCATIONS	119
CORPORATE MANAGEMENT	119
BOEHRINGER INGELHEIM GMBH	119
HISTORY	120
PRODUCTS	120
RECENT DEVELOPMENTS	120
LOCATIONS	120
CORPORATE MANAGEMENT	120
BRISTOL-MYERS SQUIBB CO.	121
HISTORY	121
PRODUCTS	121
RECENT DEVELOPMENTS	121
LOCATIONS	121
CORPORATE MANAGEMENT	122
CSL BEHRING	122
HISTORY	122
PRODUCTS	122
RECENT DEVELOPMENTS	122
LOCATIONS	123
CORPORATE MANAGEMENT	123
DAIICHI SANKYO CO. LTD.	123
HISTORY	123
PRODUCTS	123
RECENT DEVELOPMENTS	124
LOCATIONS	124
CORPORATE MANAGEMENT	124
ELI LILLY	124
HISTORY	124
PRODUCTS	125
LOCATIONS	125
CORPORATE MANAGEMENT	125
EMISPHERE TECHNOLOGIES	125
HISTORY	126
PRODUCTS	126
CORPORATE MANAGEMENT	126

TOPIC	PAGE NO.
F. HOFFMANN-LA ROCHE AG	126
HISTORY	126
PRODUCTS	127
RECENT DEVELOPMENTS	127
LOCATIONS	127
CORPORATE MANAGEMENT	127
GENENTECH	127
HISTORY	128
PRODUCTS	128
LOCATIONS	128
CORPORATE MANAGEMENT	128
GLAXOSMITHKLINE	128
HISTORY	129
PRODUCTS	129
LOCATIONS	129
CORPORATE MANAGEMENT	129
JOHNSON & JOHNSON	129
HISTORY	130
PRODUCTS	130
RECENT DEVELOPMENTS	130
LOCATIONS	130
CORPORATE MANAGEMENT	130
LIGAND PHARMACEUTICALS INC.	130
HISTORY	131
PRODUCTS	131
LOCATIONS	131
CORPORATE MANAGEMENT	131
THE MEDICINES CO.	131
HISTORY	131
PRODUCTS	132
RECENT DEVELOPMENTS	132
CORPORATE MANAGEMENT	132
MERCK	132
HISTORY	132
PRODUCTS	133
LOCATIONS	133
CORPORATE MANAGEMENT	133
MERRION PHARMACEUTICALS LTD.	133
HISTORY	133
PRODUCTS	134
LOCATIONS	134
CORPORATE MANAGEMENT	134
MICROBIX BIOSYSTEMS INC.	134
HISTORY	134
PRODUCTS	134
LOCATIONS	135
CORPORATE MANAGEMENT	135

TOPIC	PAGE NO.
NOVARTIS	135
HISTORY	135
PRODUCTS	135
RECENT DEVELOPMENTS:	136
LOCATIONS	136
CORPORATE MANAGEMENT	136
ONO PHARMACEUTICAL CO. LTD.	136
HISTORY	136
PRODUCTS	137
LOCATIONS	137
CORPORATE MANAGEMENT	137
OTSUKA PHARMACEUTICAL CO. LTD.	137
HISTORY	137
PRODUCTS	138
RECENT DEVELOPMENTS	138
LOCATIONS	138
CORPORATE MANAGEMENT	138
PFIZER INC.	139
HISTORY	139
PRODUCTS	139
RECENT DEVELOPMENTS:	140
CORPORATE MANAGEMENT	140
PORTOLA PHARMACEUTICALS	140
HISTORY	140
PRODUCTS	140
RECENT DEVELOPMENTS	140
LOCATION	141
CORPORATE MANAGEMENT	141
REVO BIOLOGICS INC.	141
HISTORY	141
PRODUCTS	141
LOCATIONS	142
CORPORATE MANAGEMENT	142
SANOVI	142
HISTORY	142
PRODUCTS	142
LOCATIONS	144
CORPORATE MANAGEMENT	144
SANTA CRUZ BIOTECHNOLOGY INC.	144
HISTORY	144
PRODUCTS	144
LOCATIONS	144
CORPORATE MANAGEMENT	144
SERVIER LABORATORIES	145
HISTORY	145
LOCATIONS	145
CORPORATE MANAGEMENT	145

TOPIC	PAGE NO.
SHIRE PHARMACEUTICALS	145
HISTORY	145
PRODUCTS	146
LOCATIONS	146
CORPORATE MANAGEMENT	146
SUN PHARMACEUTICALS	146
HISTORY	146
PRODUCTS	147
RECENT DEVELOPMENTS	147
LOCATIONS	148
CORPORATE MANAGEMENT	148
TEVA PHARMACEUTICALS LTD.	148
HISTORY	148
PRODUCTS	148
RECENT DEVELOPMENTS	149
LOCATIONS	149
CORPORATE MANAGEMENT	149
CHAPTER 8 APPENDIX A: LIST OF PATENTS	151
<i>TABLE 57 LIST OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, 2011-APRIL 2016</i>	151
CHAPTER 9 APPENDIX B: DIRECTORY OF COMPANIES COVERED IN THIS REPORT	160

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 (\$ MILLIONS)	7
TABLE 1 PRAXBIND (IDARUCIZUMAB) DRUG LABEL	12
TABLE 2 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2020 (\$ MILLIONS)	13
TABLE 3 EPIDEMIC OF CARDIOVASCULAR DISEASES	18
TABLE 4 CORONARY HEART DISEASE PROFILE	21
TABLE 5 DISTRIBUTION OF HEART DISEASE BY RACE/ETHNICITY, 2013 (%)	22
TABLE 6 ACUTE MYOCARDIAL INFARCTION DISEASE PROFILE	24
TABLE 7 VIRCHOW'S TRIAD: THREE MAIN FACTORS IN PREDISPOSITION TO PULMONARY EMBOLISM	30
TABLE 8 GLOBAL POPULATION BY SELECTED REGION, 2000-2050 (MILLIONS)	39
TABLE 9 GLOBAL POPULATION GROWTH BY SELECTED REGION, 2000-2050 (AVERAGE PERCENTAGE GROWTH PER YEAR)	40
TABLE 10 LOVENOX DRUG LABEL	49
TABLE 11 FRAGMIN DRUG LABEL	50
TABLE 12 INNOHEP DRUG LABEL	52
TABLE 13 ORGARAN DRUG LABEL	54
TABLE 14 NORMIFLO DRUG LABEL	56
TABLE 15 EMBOLEX DRUG LABEL	57
TABLE 16 FRAXIPARINE DRUG LABEL	58
TABLE 17 ARIVEN/ARTEVEN DRUG LABEL	59
TABLE 18 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 (\$ MILLIONS)	61
TABLE 19 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 (%)	63
TABLE 20 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 (%)	63
TABLE 21 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 (\$ MILLIONS)	65
TABLE 22 GLOBAL MARKET FOR LOW MOLECULAR WEIGHT HEPARIN BY REGION, THROUGH 2021 (\$ MILLIONS)	65
TABLE 23 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, THROUGH 2021 (\$ MILLIONS)	65
TABLE 24 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2015 (%)	66
TABLE 25 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2021 (%)	67
TABLE 26 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (\$ MILLIONS/%)	68
TABLE 27 PLAVIX DRUG LABEL	71
TABLE 28 PLETAL DRUG LABEL	73
TABLE 29 EFFIENT DRUG LABEL	74
TABLE 30 BRILINTA DRUG LABEL	75
TABLE 31 INTEGRILIN DRUG LABEL	77
TABLE 32 AGGRASTAT DRUG LABEL	78
TABLE 33 REOPRO DRUG LABEL	80
TABLE 34 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, THROUGH 2021 (\$ MILLIONS)	81
TABLE 35 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2015 (%)	82
TABLE 36 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2021 (%)	83

TABLE HEADING	PAGE NO.
TABLE 37 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, THROUGH 2021 (\$ MILLIONS)	85
TABLE 38 GLOBAL MARKET FOR ORAL ANTIPLATELET DRUGS BY REGION, THROUGH 2021 (\$ MILLIONS)	86
TABLE 39 GLOBAL MARKET FOR IV ANTIPLATELET DRUGS BY REGION, THROUGH 2021 (\$ MILLIONS)	86
TABLE 40 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2015 (%)	86
TABLE 41 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2021 (%)	87
TABLE 42 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (\$ MILLIONS/%)	88
TABLE 43 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, THROUGH 2021 (\$ MILLIONS)	96
TABLE 44 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 (%)	97
TABLE 45 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 (%)	98
TABLE 46 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, THROUGH 2021 (\$ MILLIONS)	99
TABLE 47 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, 2015 (%)	100
TABLE 48 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 (%)	100
TABLE 49 GLOBAL MARKET FOR THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 (\$ MILLIONS/%)	101
TABLE 50 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 (\$ MILLIONS)	105
TABLE 51 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2015 (%)	106
TABLE 52 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2021 (%)	107
TABLE 53 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 (\$ MILLIONS)	108
TABLE 54 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 (%)	109
TABLE 55 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 (%)	110
TABLE 56 GLOBAL MARKET FOR ANTITHROMBIN/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (\$ MILLIONS/%)	111
TABLE 57 LIST OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, 2011-APRIL 2016	151

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015-2021 (\$ MILLIONS)	7
FIGURE 1 COMPANY SHARES OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, JAN. 2011 TO APRIL 2016 (%)	14
FIGURE 2 COMPANY SHARES OF PATENTS ON ANTICOAGULANTS, JAN. 2011 TO APRIL 2016 (%)	15
FIGURE 3 GLOBAL POPULATION GROWTH BY SELECTED REGION, 2000-2050 (AVERAGE PERCENTAGE GROWTH)	40
FIGURE 4 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, 2015-2021 (\$ MILLIONS)	61
FIGURE 5 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 (%)	63
FIGURE 6 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 (%)	64
FIGURE 7 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, 2015-2021 (\$ MILLIONS)	65
FIGURE 8 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2015 (%)	66
FIGURE 9 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2021 (%)	67
FIGURE 10 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)	68
FIGURE 11 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, 2015-2021 (\$ MILLIONS)	81
FIGURE 12 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2015 (%)	83
FIGURE 13 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2021 (%)	84
FIGURE 14 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, 2015-2021 (\$ MILLIONS)	85
FIGURE 15 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2015 (%)	86
FIGURE 16 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2021 (%)	88
FIGURE 17 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)	88
FIGURE 18 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, 2015-2021 (\$ MILLIONS)	96
FIGURE 19 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 (%)	97
FIGURE 20 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 (%)	98
FIGURE 21 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, 2015-2021 (\$ MILLIONS)	99
FIGURE 22 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, 2015 (%)	100
FIGURE 23 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 (%)	101
FIGURE 24 GLOBAL MARKET SHARES OF THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 (%)	101
FIGURE 25 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2015-2021 (\$ MILLIONS)	105
FIGURE 26 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2015 (%)	106
FIGURE 27 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2021 (%)	107
FIGURE 28 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015-2021 (\$ MILLIONS)	108

FIGURE TITLE	PAGE NO.
FIGURE 29 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 (%)	109
FIGURE 30 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 (%)	110
FIGURE 31 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)	111